John Garner

PolySciTech Poly(caprolactone) used as part of development of a theranostic nanoparticle system as a potential treatment for cancer

Blog Post created by John Garner on Sep 13, 2016

PolySciTech division of Akina, Inc. ( provides a wide array of biodegradable polymers. Recently, PCL from PolySciTech (PolyVivo catalog AP113) was used as part of development of an NIR sensitive nanoparticle system for delivery of paclitaxel. This research holds promise for improved therapeutic strategies. Read more: Su, Jinghan, Huiping Sun, Qingshuo Meng, Qi Yin, Pengcheng Zhang, Zhiwen Zhang, Haijun Yu, and Yaping Li. "Bioinspired Nanoparticles with NIR‐Controlled Drug Release for Synergetic Chemophotothermal Therapy of Metastatic Breast Cancer." Advanced Functional Materials (2016).


   “Abstract: Optimal nanosized drug delivery systems (NDDS) require long blood circulation and controlled drug release at target lesions for efficient anticancer therapy. Red blood cell (RBC) membrane-camouflaged nanoparticles (NPs) can integrate flexibility of synergetic materials and highly functionality of RBC membrane, endowed with many unique advantages for drug delivery. Here, new near-infrared (NIR)-responsive RBC membrane-mimetic NPs with NIR-activated cellular uptake and controlled drug release for treating metastatic breast cancer are reported. An NIR dye is inserted in RBC membrane shells, and the thermoresponsive lipid is employed to the paclitaxel (PTX)-loaded polymeric cores to fabricate the RBC-inspired NPs. The fluorescence of dye in the NPs can be used for in vivo tumor imaging with an elongated circulating halftime that is 12.3-folder higher than that of the free dye. Under the NIR laser stimuli, the tumor cellular uptake of NPs is significantly enhanced to 2.1-fold higher than that without irradiation. The structure of the RBC-mimetic NPs can be destroyed by the light-induced hyperthermia, triggered rapid PTX release (45% in 30 min). These RBC-mimetic NPs provide a synergetic chemophotothermal therapy, completely inhibited the growth of the primary tumor, and suppress over 98% of lung metastasis in vivo, suggesting it to be an ideal NDDS to fight against metastatic breast cancer.”